国际肿瘤学杂志

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (1): 27-.doi: 10.3760/cma.j.issn.1673-422X.2018.01.006

• 论著 • 上一篇    下一篇

血清LCN2与PSA联合检测对前列腺癌的 诊断价值

毕泗成，刘浩，张鹏，李喆，买铁军，祝志臻   

  1. 100028 北京市煤炭总医院泌尿外科
  • 出版日期:2018-01-08 发布日期:2018-02-12
  • 通讯作者: 毕泗成 E-mail:bsc197422@qq.com

Diagnostic value of serum lipocalin 2 combined with prostatespecific antigen in prostate cancer

Bi Sicheng*, Liu Hao, Zhang Peng, Li Zhe, Mai Tiejun, Zhu Zhizhen   

  1. epartment of Urology, Meitan General Hospital of Beijing, Beijing 100028, China
  • Online:2018-01-08 Published:2018-02-12
  • Contact: Bi Sicheng E-mail:bsc197422@qq.com

PDF

892

摘要： 目的探讨血清脂质运载蛋白2（LCN2）联合前列腺特异抗原(PSA)检测对前列腺癌（PCa）的诊断价值。方法采用酶联免疫吸附试验（ELISA）检测PCa患者（PCa组，n=82）、良性前列腺增生患者（BPH组，n=40）、健康体检者（NC组，n=30）血清LCN2水平；采用化学发光法检测各组PSA水平；通过受试者工作特征（ROC）曲线分析LCN2联合PSA检测对PCa的诊断价值，并分析LCN2与PCa患者临床病理特征的关系。结果PCa组、BPH组和NC组患者血清LCN2水平分别为（88.97±40.83）pg/ml、（53.12±25.66）pg/ml、（13.34±4.86）pg/ml（F=61.306，P＜0.001），PCa组LCN2水平明显高于BPH组和NC组（均P＜0.001）。3组患者血清PSA水平分别为（17.65±8.43）ng/ml、（11.27±3.56）ng/ml、（2.61±0.87）ng/ml（F=60.959，P＜0.001），PCa组PSA水平明显高于BPH组和NC组（均P＜0.001）。PCa患者血清LCN2与PSA水平之间呈正相关（r=0.360，P＜0.001）。不同Gleason评分、TNM分期、远处转移的PCa患者血清LCN2水平之间差异有统计学意义（F=8.546，P＜0.001；t=3.421，P=0.001；t=3.622，P=0.010）。血清LCN2的曲线下面积（AUC）为0.763（95%CI为0.677～0.850，P＜0.001），敏感性为62.2%，特异性为85.0%；血清PSA的AUC值为0.750（95%CI为0.665～0.836，P＜0.001），敏感性为51.2%，特异性为87.5%；血清LCN2和PSA联合检测的AUC值为0.822（95%CI为0.749～0.895，P＜0.001）。结论PCa患者血清LCN2水平增高，与PCa的进展密切相关，是诊断PCa潜在的血清肿瘤标志物，LCN2和PSA联合检测有助于提高PCa的早期诊断能力。

关键词: 前列腺肿瘤, 前列腺特异抗原, 脂质运载蛋白2

Abstract: ObjectiveTo investigate the diagnostic value of lipocalin 2 (LCN2) combined with prostatespecific antigen (PSA) in prostate cancer (PCa). MethodsEnzymelinked immunosorbent assay (ELISA) was used to determine the levels of serum LCN2 in patients with PCa (PCa group, n=82), patients with benign prostatic hyperplasia (BPH group, n=40) and healthy subjects (NC group, n=30). The levels of serum PSA were measured by chemiluminescence. The diagnostic value of LCN2 combined with PSA in PCa was analyzed by the receiver operating characteristic (ROC) curve. The relationship between the level of LCN2 and clinical parameters in PCa patients was analyzed. ResultsThe levels of serum LCN2 in PCa group, BPH group and NC group were (88.97±40.83) pg/ml, (53.12±25.66) pg/ml, (13.34±4.86) pg/ml (F=61.306, P<0.001). The level of LCN2 in PCa group was significantly higher than that in BPH group and NC group (both P<0.001). The levels of serum PSA in PCa group, BPH group and NC group were (17.65±8.43) ng/ml, (11.27±3.56) ng/ml, (2.61±0.87) ng/ml (F=60.959, P<0.001). The level of serum PSA in PCa group was significantly higher than that in BPH group and NC group (both P<0.001). There was positive correlation between serum LCN2 and PSA levels (r=0.360, P＜0.001). The levels of serum LCN2 in PCa patients with different Gleason score, TNM stage and distant metastasis were significantly different (F=8.546, P＜0.001; t=3.421, P=0.001; t=3.622, P=0.010). The area under the curve (AUC) of serum LCN2 was 0.763 (95%CI: 0.6770.850, P＜0.001). The sensitivity and specificity of serum LCN2 were 62.2% and 85.0%. The AUC of PSA was 0.750 (95%CI: 0.6650.836, P＜0.001). The sensitivity and specificity of serum PSA were 51.2% and 87.5%. The AUC of LCN2 combined with PSA was 0.822 (95%CI: 0.7490.895, P＜0.001). ConclusionSerum LCN2 level in the patients with PCa is significantly higher, which participates in tumor invasion. LCN2 may be a potential serum marker for the diagnosis of PCa. Combined detection of LCN2 and PSA contributes to the early diagnosis of PCa.

Key words: Prostate neoplasms, Prostatespecific antigen, Lipocalin 2